| Two phase 3 trials of dupilumab versus placebo in atopic dermatitis EL Simpson, T Bieber, E Guttman-Yassky, LA Beck, A Blauvelt, MJ Cork, ... New England Journal of Medicine 375 (24), 2335-2348, 2016 | 1741 | 2016 |
| Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and … KB Gordon, B Strober, M Lebwohl, M Augustin, A Blauvelt, Y Poulin, ... The Lancet 392 (10148), 650-661, 2018 | 600 | 2018 |
| Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled … C Paul, J Cather, M Gooderham, Y Poulin, U Mrowietz, C Ferrandiz, ... British Journal of Dermatology 173 (6), 1387-1399, 2015 | 481 | 2015 |
| Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial R Bissonnette, KA Papp, Y Poulin, M Gooderham, M Raman, L Mallbris, ... British Journal of Dermatology 175 (5), 902-911, 2016 | 480 | 2016 |
| North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I … A Alikhan, C Sayed, A Alavi, R Alhusayen, A Brassard, C Burkhart, ... Journal of the American Academy of Dermatology 81 (1), 76-90, 2019 | 474 | 2019 |
| Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2) A Wollenberg, A Blauvelt, E Guttman‐Yassky, M Worm, C Lynde, ... British Journal of Dermatology 184 (3), 437-449, 2021 | 414 | 2021 |
| Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) RE Kalb, DF Fiorentino, MG Lebwohl, J Toole, Y Poulin, AD Cohen, ... JAMA dermatology 151 (9), 961-969, 2015 | 398 | 2015 |
| Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis S Tyring, KB Gordon, Y Poulin, RG Langley, AB Gottlieb, M Dunn, ... Archives of dermatology 143 (6), 719-726, 2007 | 395 | 2007 |
| Interleukin 17A: toward a new understanding of psoriasis pathogenesis CW Lynde, Y Poulin, R Vender, M Bourcier, S Khalil Journal of the American Academy of Dermatology 71 (1), 141-150, 2014 | 388 | 2014 |
| Topical treatment of actinic keratoses with 3· 0% diclofenac in 2· 5% hyaluronan gel JK Rivers, J Arlette, N Shear, L Guenther, W Carey, Y Poulin British Journal of Dermatology 146 (1), 94-100, 2002 | 275 | 2002 |
| Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus JI Silverberg, A Pinter, G Pulka, Y Poulin, JD Bouaziz, A Wollenberg, ... Journal of Allergy and Clinical Immunology 145 (1), 173-182, 2020 | 235 | 2020 |
| Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for … K Gordon, K Papp, Y Poulin, Y Gu, S Rozzo, EH Sasso Journal of the American Academy of Dermatology 66 (2), 241-251, 2012 | 215 | 2012 |
| A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris WS Douglas, Y Poulin, J Decroix, JP Ortonne, U Mrowietz, W Gulliver, ... Acta dermato-venereologica 82 (2), 131-135, 2002 | 214 | 2002 |
| Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 … RG Langley, M Lebwohl, GG Krueger, PO Szapary, Y Wasfi, D Chan, ... British Journal of Dermatology 172 (5), 1371-1383, 2015 | 210 | 2015 |
| Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL‐17A inhibition in psoriasis K Reich, KA Papp, RT Matheson, JH Tu, R Bissonnette, M Bourcier, ... Experimental dermatology 24 (7), 529-535, 2015 | 208 | 2015 |
| SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis EL Simpson, T Bieber, E Guttman-Yassky, LA Beck, A Blauvelt, MJ Cork, ... N Engl J Med 375 (24), 2335-2348, 2016 | 195 | 2016 |
| Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial B Sigurgeirsson, A Boznanski, G Todd, A Vertruyen, MLA Schuttelaar, ... Pediatrics 135 (4), 597-606, 2015 | 190 | 2015 |
| Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris ZD Draelos, E Carter, JM Maloney, B Elewski, Y Poulin, C Lynde, ... Journal of the American academy of dermatology 56 (3), 439. e1-439. e10, 2007 | 190 | 2007 |
| Development and validation of a comprehensive acne severity scale JKL Tan, J Tang, K Fung, AK Gupta, DR Thomas, S Sapra, C Lynde, ... Journal of cutaneous medicine and surgery 11 (6), 211-216, 2007 | 174 | 2007 |
| Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies … AB Gottlieb, A Blauvelt, D Thaçi, CL Leonardi, Y Poulin, J Drew, ... Journal of the American Academy of Dermatology 79 (2), 302-314. e6, 2018 | 164 | 2018 |
